Halozyme Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio13.7017.3438.0614.0544.66
Forward P/E10.389.7721.9217.8925.20
P/S Ratio5.995.8911.6512.7621.54
P/B Ratio16.7258.2645.3128.7338.16
Price/Tangible Book28.7338.16
Price/FCF12.9913.0832.7018.99108.87
Price/OCF12.7012.5632.0418.90103.95
PEG Ratio0.410.410.410.460.55
Enterprise Value Ratios
EV/Revenue6.857.1513.5412.9121.74
EV/EBITDA11.0914.2226.6020.6339.89
EV/EBIT12.6117.4330.8920.7440.33
EV/FCF14.8415.8837.9919.20109.86
Profitability & Returns
Return on Equity (ROE)1.98%2.22%1.10%2.31%1.06%
Return on Assets (ROA)0.18%0.12%0.12%0.20%0.16%
Return on Invested Capital (ROIC)0.34%0.21%0.28%1.06%1.09%
Return on Capital Employed (ROCE)0.29%0.21%0.17%0.28%0.91%
Leverage & Solvency Ratios
Debt/Equity4.2218.279.074.472.66
Debt/EBITDA2.423.594.543.152.71
Debt/FCF3.284.106.552.957.59
Liquidity Ratios
Current Ratio7.806.635.657.911.32
Quick Ratio6.505.074.547.101.10
Efficiency Ratios
Asset Turnover0.540.460.450.530.47
Inventory Turnover1.772.362.672.041.72
Yield & Distribution Ratios
Earnings Yield0.07%0.06%0.03%0.07%0.02%
FCF Yield0.08%0.08%0.03%0.05%0.01%
Buyback Yield0.04%0.05%0.04%-0.04%0.02%